[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Lymphoma: non-Hodgkin's lymphoma,Lenalidomide,CD47,Macrophages,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>P. Strati<\/b>, L. Feng, D. Chihara, J. Westin, S. Ahmed, L. Fayad, J. Henderson, J. Davidson, E. McChesney, L. Nastoupil, S. Neelapu, C. Flowers; <br\/>UT MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"5bdbb73e-8015-47e3-9cef-36de093c983d","ControlNumber":"10285","DisclosureBlock":"<b>&nbsp;P. Strati, <\/b> <br><b>Astrazeneca, Sobi, ADC Therapeutics, ALX Oncology<\/b> Grant\/Contract. <br><b>Roche Genentech, Ipsen, Kite-Gilead, Astrazeneca, Ipsen, Sobi<\/b> Other, Advisory Boards.<br><b>L. Feng, <\/b> None..<br><b>D. Chihara, <\/b> None..<br><b>J. Westin, <\/b> None..<br><b>S. Ahmed, <\/b> None..<br><b>L. Fayad, <\/b> None..<br><b>J. Henderson, <\/b> None..<br><b>J. Davidson, <\/b> None..<br><b>E. McChesney, <\/b> None..<br><b>L. Nastoupil, <\/b> None..<br><b>S. Neelapu, <\/b> None..<br><b>C. Flowers, <\/b> None.","End":"4\/9\/2024 2:40:00 PM","HasWebcast":null,"Highlights":[],"Id":"11412","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT037","PresenterBiography":null,"PresenterDisplayName":"Paolo Strati, MD","PresenterKey":"97e6dde2-2e43-47fa-be2f-11de4af3f7e5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT037. A phase I investigator-initiated trial of evorpacept (ALX148), lenalidomide and rituximab for patients with relapsed or refractory B-cell non-Hodgkin lymphoma","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  2:30PM","SessionId":"665","SessionOnDemand":"False","SessionTitle":"Novel Agents and Emerging Therapeutic Strategies","ShowChatLink":"false","Start":"4\/9\/2024 2:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase I investigator-initiated trial of evorpacept (ALX148), lenalidomide and rituximab for patients with relapsed or refractory B-cell non-Hodgkin lymphoma","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"6b9a25a1-d9b6-49f8-a520-a55f345f86ab","ControlNumber":"12158","DisclosureBlock":"","End":"4\/9\/2024 2:45:00 PM","HasWebcast":null,"Highlights":[],"Id":"11857","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"2","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  2:30PM","SessionId":"665","SessionOnDemand":"False","SessionTitle":"Novel Agents and Emerging Therapeutic Strategies","ShowChatLink":"false","Start":"4\/9\/2024 2:40:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),GC,SKB264,Trop-2,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Rodon<\/b><sup>1<\/sup>, Z. A. Wainberg<sup>2<\/sup>, M. Zhang<sup>3<\/sup>, T. Liu<sup>4<\/sup>, B. Liu<sup>5<\/sup>, G. Yu<sup>6<\/sup>, Y. Yin<sup>7<\/sup>, S. Zhang<sup>8<\/sup>, Y. Mi<sup>9<\/sup>, X. Li<sup>10<\/sup>, X. Wang<sup>11<\/sup>, Y. Liu<sup>12<\/sup>, X. Wang<sup>13<\/sup>, Y. Cheng<sup>14<\/sup>, X. Zhang<sup>15<\/sup>, Y. Yang<sup>15<\/sup>, J. Ge<sup>15<\/sup>, O. O. Akala<sup>16<\/sup>, E. Chartash<sup>16<\/sup>, J. Li<sup>17<\/sup>; <br\/><sup>1<\/sup>University of Texas MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>University of California Los Angeles, Los Angeles, CA, <sup>3<\/sup>The Second Hospital of Anhui Medical University, Hefei, China, <sup>4<\/sup>Zhongshan Hospital Fudan University, Shanghai, China, <sup>5<\/sup>Shandong Cancer Hospital, Jinan, China, <sup>6<\/sup>Weifang People's Hospital, Weifang, China, <sup>7<\/sup>Jiangsu Province Hospital, Nanjing, China, <sup>8<\/sup>West China Hospital of Sichuan University, Chengdu, China, <sup>9<\/sup>The First Affiliated Hospital of Xiamen University, Xiamen, China, <sup>10<\/sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, <sup>11<\/sup>Sir Run Run Shaw Hospital, Hangzhou, China, <sup>12<\/sup>The first Hospital of China Medical University, Shenyang, China, <sup>13<\/sup>Xuzhou Central Hospital, Xuzhou, China, <sup>14<\/sup>Jilin Cancer Hospital, Changchun, China, <sup>15<\/sup>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, China, <sup>16<\/sup>Merck & Co., Inc., Rahway, NJ, USA, Rahway, NJ, <sup>17<\/sup>Shanghai East Hospital, Shanghai, China","CSlideId":"","ControlKey":"33f7abb8-f544-48c2-ae2a-89053b4c98ef","ControlNumber":"10344","DisclosureBlock":"<b>&nbsp;J. Rodon, <\/b> <br><b>European Society for Medical Oncology; Loxo Oncology<\/b> Travel. <br><b>Ellipses Pharma; Molecular Partners; IONCTURA; Sardona; Mekanistic; Amgen; Merus; MonteRosa; Aadi; Bridgebio<\/b> Other, Receiving consulting and travel fees. <br><b>Vall d'Hebron Institute of Oncology\/Ministero De Empleo Y Seguridad Social; Chinese University of Hong Kong; Boxer Capital; LLC; Tang Advisors; LLC; Guidepoint<\/b> Other, Consulting fees. <br><b>Blueprint Medicines; Merck Sharp & Dohme; Hummingbird; AstraZenneca; Yingli; Vall d'Hebron Institute of Oncology\/Cancer Core Europe<\/b> Other, Research funding. <br><b>Cancer Core Europe; Symphogen; BioAlta; Pfizer; Kelun-Biotech; GlaxoSmithKline; Taiho; Roche Pharmaceuticals; Hummingbird; Yingli; Bicycle Therapeutics; Merus; AadiBioscience; ForeBio; Loxo Oncology;<\/b> Serving as investigator in clinical trials. <br><b>Z. A. Wainberg, <\/b> <br><b>AstraZeneca<\/b> Other, Consultant. <br><b>Bristol-Myers Squibb<\/b> Other, Consultant. <br><b>Novartis<\/b> Other, Consultant. <br><b>AngioDynamics, Inc<\/b> Other, Consultant. <br><b>Eli LIly<\/b> Other, Consultant. <br><b>Astellas Pharma<\/b> Other, Consultant. <br><b>Daichi Sankyo Company<\/b> Other, Consultant. <br><b>Ipsen Biopharmaceuticals, Inc.<\/b> Other, Consultant. <br><b>Amgen<\/b> Other, Consultant. <br><b>Merck<\/b> Other, Consultant.<br><b>M. Zhang, <\/b> None..<br><b>T. Liu, <\/b> None..<br><b>B. Liu, <\/b> None..<br><b>G. Yu, <\/b> None..<br><b>Y. Yin, <\/b> None..<br><b>S. Zhang, <\/b> None..<br><b>Y. Mi, <\/b> None..<br><b>X. Li, <\/b> None..<br><b>X. Wang, <\/b> None..<br><b>Y. Liu, <\/b> None..<br><b>X. Wang, <\/b> None..<br><b>Y. Cheng, <\/b> None.&nbsp;<br><b>X. Zhang, <\/b> <br><b>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.<\/b> Employment. <br><b>Y. Yang, <\/b> <br><b>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.<\/b> Employment. <br><b>J. Ge, <\/b> <br><b>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.<\/b> Employment. <br><b>O. O. Akala, <\/b> <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>E. Chartash, <\/b> <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment.<br><b>J. Li, <\/b> None.","End":"4\/9\/2024 2:55:00 PM","HasWebcast":null,"Highlights":[],"Id":"11413","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT038","PresenterBiography":null,"PresenterDisplayName":"Jordi Ahnert, MD, PhD","PresenterKey":"c57930a0-d061-400f-be6c-f41ccc07d65f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT038. Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a Phase 2 study","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  2:30PM","SessionId":"665","SessionOnDemand":"False","SessionTitle":"Novel Agents and Emerging Therapeutic Strategies","ShowChatLink":"false","Start":"4\/9\/2024 2:45:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a Phase 2 study","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"dd5b1fce-7e65-44f9-9a7e-0a657fd22b3f","ControlNumber":"12159","DisclosureBlock":"","End":"4\/9\/2024 3:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11858","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"4","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  2:30PM","SessionId":"665","SessionOnDemand":"False","SessionTitle":"Novel Agents and Emerging Therapeutic Strategies","ShowChatLink":"false","Start":"4\/9\/2024 2:55:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT07-02 Phase II clinical trials in pediatric cancer,,"},{"Key":"Keywords","Value":"ALK,Pediatric cancers,Brain\/central nervous system cancers,Solid tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"F. Doz<sup>1<\/sup>, M. Casanova<sup>2<\/sup>, K.-N. Koh<sup>3<\/sup>, K. Nysom<sup>4<\/sup>, A. Canete<sup>5<\/sup>, H. Kang<sup>6<\/sup>, M. Karajannis<sup>7<\/sup>, D. Hargrave<sup>8<\/sup>, N. Corradini<sup>9<\/sup>, Y. Wu<sup>10<\/sup>, T. Ruf<sup>11<\/sup>, J. Noe<sup>11<\/sup>, G. Manzella<sup>11<\/sup>, T. Xu<sup>11<\/sup>, N. Kassir<sup>12<\/sup>, Y. Tai<sup>12<\/sup>, <b>F. Mussai<\/b><sup>13<\/sup>, C. Devlin<sup>13<\/sup>, A. Gajjar<sup>14<\/sup>; <br\/><sup>1<\/sup>SIREDO Center (Care, Innovation, Research in Pediatric, Adolescent and Young Adults Oncology), Institut Curie, Paris, France, <sup>2<\/sup>Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy, <sup>3<\/sup>Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Korea, Republic of, <sup>4<\/sup>Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, <sup>5<\/sup>Hospital Universitari i Politecnic La Fe, Valencia, Spain, <sup>6<\/sup>Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Children’s Hospital, Seoul, Korea, Republic of, <sup>7<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY, <sup>8<\/sup>Great Ormond Street Hospital, London, United Kingdom, <sup>9<\/sup>Institut d’Hémato-Oncologie Pédiatrique, Centre Léon Bérard, Lyon, France, <sup>10<\/sup>Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, <sup>11<\/sup>F. Hoffmann-La Roche Ltd, Basel, Switzerland, <sup>12<\/sup>Genentech, South San Francisco, CA, <sup>13<\/sup>F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom, <sup>14<\/sup>St. Jude Children’s Research Hospital, Memphis, TN","CSlideId":"","ControlKey":"d126d998-03d7-4903-b1fe-c2db51e1a161","ControlNumber":"9527","DisclosureBlock":"<b>&nbsp;F. Doz, <\/b> <br><b>Servier<\/b> Payment for consulting. <br><b>IPSEN<\/b> Payment for iDMC. <br><b>Roche-Genentech<\/b> Payment for Advisory Board. <br><b>BMS<\/b> Payment for Advisory Board. <br><b>Loxo<\/b> Payment for Advisory Board. <br><b>Bayer<\/b> Payment for Advisory Board. <br><b>Onxeo<\/b> Payment for Advisory Board. <br><b>Syneth-Innove<\/b> Payment for Advisory Board. <br><b>M. Casanova, <\/b> <br><b>Astra Zeneca<\/b> Advisory role. <br><b>Servier<\/b> Advisory role. <br><b>Bayer<\/b> Advisory role. <br><b>Pfizer<\/b> Advisory role.<br><b>K. Koh, <\/b> None.&nbsp;<br><b>K. Nysom, <\/b> <br><b>Bayer<\/b> Payment for teaching, Payment for Advisory Board. <br><b>Y-mabs<\/b> Payment for advisory board and consulting. <br><b>EUSA pharma<\/b> Payment for advisory board. <br><b>Lilly<\/b> Serving on data monitoring committee.<br><b>A. Canete, <\/b> None..<br><b>H. Kang, <\/b> None.&nbsp;<br><b>M. Karajannis, <\/b> <br><b>QED Theapeutics<\/b> Payments for medical advisory board and\/or consultant. <br><b>CereXis<\/b> Payments for medical advisory board and\/or consultant. <br><b>Recursion<\/b> Payments for medical advisory board and\/or consultant. <br><b>Alexion<\/b> Payments for medical advisory board and\/or consultant. <br><b>Cardinal Health<\/b> Payments for medical advisory board and\/or consultant. <br><b>Physicians Education Resource<\/b> Payments for medical advisory board and\/or consultant. <br><b>Medscape<\/b> Payments for medical advisory board and\/or consultant. <br><b>D. Hargrave, <\/b> <br><b>Astra Zeneca<\/b> Payments for consulting\/advisory boards. <br><b>Alexion<\/b> Payments for consulting\/advisory boards. <br><b>Bayer<\/b> Payments for consulting\/advisory boards. <br><b>Biodexa<\/b> Payments for consulting\/advisory boards. <br><b>Novartis<\/b> Payments for consulting\/advisory boards. <br><b>Roche Genentech<\/b> Payments for consulting\/advisory boards.<br><b>N. Corradini, <\/b> None..<br><b>Y. Wu, <\/b> None.&nbsp;<br><b>T. Ruf, <\/b> <br><b>Roche-Genentech<\/b> Employment, Stock. <br><b>J. Noe, <\/b> <br><b>Roche-Genentech<\/b> Employment, Stock. <br><b>G. Manzella, <\/b> <br><b>Roche-Genentech<\/b> Employment, Stock. <br><b>T. Xu, <\/b> <br><b>Roche-Genentech<\/b> Employment, Stock. <br><b>N. Kassir, <\/b> <br><b>Roche-Genentech<\/b> Employment, Stock. <br><b>Y. Tai, <\/b> <br><b>Genentech<\/b> Employment. <br><b>F. Mussai, <\/b> <br><b>F. Hoffmann-La Roche Ltd<\/b> Employment, Stock. <br><b>C. Devlin, <\/b> <br><b>F. Hoffmann-La Roche Ltd<\/b> Employment, Stock. <br><b>A. Gajjar, <\/b> <br><b>Day One Therapeutics<\/b> Payments for advisory board. <br><b>Roche Genentech<\/b> Payments for advisory board.","End":"4\/9\/2024 3:10:00 PM","HasWebcast":null,"Highlights":[],"Id":"11414","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT039","PresenterBiography":null,"PresenterDisplayName":"Francis Mussai","PresenterKey":"00ea29be-9061-44ac-b69b-a0b5b1b6edac","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT039. Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Data from the iMATRIX Alectinib Phase I\/II open-label, multi-center study","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  2:30PM","SessionId":"665","SessionOnDemand":"False","SessionTitle":"Novel Agents and Emerging Therapeutic Strategies","ShowChatLink":"false","Start":"4\/9\/2024 3:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Data from the iMATRIX Alectinib Phase I\/II open-label, multi-center study","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"03312352-d55d-4a5f-b823-d0f7ae8d03be","ControlNumber":"12160","DisclosureBlock":"","End":"4\/9\/2024 3:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"11859","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"6","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  2:30PM","SessionId":"665","SessionOnDemand":"False","SessionTitle":"Novel Agents and Emerging Therapeutic Strategies","ShowChatLink":"false","Start":"4\/9\/2024 3:10:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"NSCLC,KRAS,GSTP1,siRNA,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>L. Bazhenova<\/b><sup>1<\/sup>, H. Mamdani<sup>2<\/sup>, A. Chiappori<sup>3<\/sup>, A. Spira<sup>4<\/sup>, W. Iams<sup>5<\/sup>, A. Tolcher<sup>6<\/sup>, M. Barve<sup>7<\/sup>, A. Gabayan<sup>8<\/sup>, A. Vandross<sup>9<\/sup>, C. Cina<sup>10<\/sup>, Y. Cohen-Arazi<sup>10<\/sup>, Z. Albaugh<sup>11<\/sup>, A. Huynh<sup>10<\/sup>, J. Gullbo<sup>11<\/sup>, S. Zabludoff<sup>10<\/sup>; <br\/><sup>1<\/sup>UC San Diego Moores Cancer Center, San Diego, CA, <sup>2<\/sup>Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, <sup>3<\/sup>Moffitt Cancer Center, Tampa, FL, <sup>4<\/sup>Next Oncology Virginia and Department of Medical Oncology, Virginia Cancer Specialists, Fairfax, VA, <sup>5<\/sup>Vanderbilt-Ingram Cancer Center, Nashville, TN, <sup>6<\/sup>NEXT Oncology, San Antonio, TX, <sup>7<\/sup>Mary Crowley Cancer Research, Dallas, TX, <sup>8<\/sup>Beverly Hills Cancer Center, Beverly Hills, CA, <sup>9<\/sup>NEXT Oncology, Austin, TX, <sup>10<\/sup>Nitto BioPharma, Inc., San Diego, CA, <sup>11<\/sup>Theradex Oncology, Princeton, NJ","CSlideId":"","ControlKey":"c18e0c4e-7f03-48c2-84e7-12c479a8d20f","ControlNumber":"9701","DisclosureBlock":"<b>&nbsp;L. Bazhenova, <\/b> <br><b>UC San Diego Moores Cancer Center<\/b> Employment. <br><b>Pfizer; Janssen; Anheart; Gilead; Sanofi; Teligene; Boehringer Ingelheim; Neuvogen; Bayer; BioAtla; Summit therapeutics; Merck; Abbvie; Regeneron; Genentech; Intervenn; Novocure<\/b> Other, Advisory Boards. <br><b>H. Mamdani, <\/b> <br><b>Barbara Ann Karmanos Cancer Institute, Wayne State University<\/b> Employment. <br><b>AstraZeneca, Genentech, Daiichi Sankyo, Zentalis<\/b> Other, Advisory Board. <br><b>A. Chiappori, <\/b> <br><b>Moffitt Cancer Center<\/b> Employment. <br><b>Merck<\/b> Stock. <br><b>Jazz Pharmaceuticals; Ailleron; Sanofi\/Regeneron; GI Therapeutics; Merus; Amgen; Mirati Therapeutics; Daiichi Sankyo\/Lily;<\/b> Other, Consultant or Advisory. <br><b>Genetech; Takeda; Blueprint Medicines; Amgen<\/b> Other, Speaker's Bureau. <br><b>Bristol-Myers Squibb; AstraZeneca; Jazz Pharmaceuticals<\/b> Other, Research Funding. <br><b>Takeda; Amgen<\/b> Other. <br><b>A. Spira, <\/b> <br><b>Next Oncology Virginia and Department of Medical Oncology, Virginia Cancer Specialists<\/b> Employment. <br><b>Incyte; Amgen; Novartis; Mirati Therapeutics; Gritstone Oncology; Jazz Pharmaceuticals; Takeda; Janssen Research and Development; Mersana; Gritstone Bio; Daiichi Sankyo\/AstraZeneca; Regeneron; Lilly<\/b> Other, Consultant. <br><b>Black Diamond Therapeutics; Sanofi; Array BioPharma; AstraZeneca\/MedImmune; Merck; Bristol-Myers Squibb; Blueprint Medicines<\/b> Other, Consultant. <br><b>LAM Therapeutics; Regeneron; Roche; AstraZeneca; Boehringer Ingelheim; Astellas Pharma; MedImmune; Novartis; Incyte; Abbvie<\/b> Grant\/Contract. <br><b>Ignyta; Takeda; Macrogenics; CytomX Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Loxo; Arch Therapeutics; Gritstone<\/b> Grant\/Contract. <br><b>Plexxikon; Amgen; Loxo; Daiichi Sankyo; ADCT; Janssen Oncology; Mirati Therapeutics; Rubius; Synthekine; Mersana; Blueprint Medicines; Alkermes<\/b> Grant\/Contract. <br><b>Revolution Medicines; Medikine; Synthekine; Black Diamond Therapeutics; BluPrint Oncology; Nalo Therapeutics; Scorpion Therapeutics;  ArriVent Biopharma; Revolution Medicines<\/b> Grant\/Contract. <br><b>Eli Lilly<\/b> Stock. <br><b>CytomX Therapeutics; AstraZeneca\/MedImmune; Merck; Takeda; Amgen; Janssen Oncology; Novartis; Bristol-Myers Squibb; Bayer<\/b> Other, Honoraria. <br><b>W. Iams, <\/b> <br><b>Vanderbilt-Ingram Cancer Center<\/b> Employment. <br><b>Merus; Bristol Myers Squibb; Daichii Sankyo; Guardant; Tempus; EMD Serono; Amgen; Sanofi; NovoCure; Genentech; AstraZeneca; Catalyst; Jazz Pharma; Elevation Oncology; Janssen<\/b> Other, Consultant. <br><b>A. Tolcher, <\/b> <br><b>ABBVIE, Inc; Aclaris Therapeutics; Affinia Therapeutics, Inc; AGENUS; Inc., ASANA BIOSCIENCES; ASCENTAGE; Astex Pharmaceuticalsm; Axlmmune;  Bayer; Blu Print Oncology; Daiichi Sankyo, Inc.;<\/b> Other, Consulting. <br><b>Exelixis, Inc.; GILDE HEALTHCARE PARTNERS; HBM PARTNERS; Ikena Oncology; Immuneering; Immunomet Therapeutics, Inc.; Impact Therapeutics US, Inc.; Karma Oncology B.V.; Kirilys Therapeutics, Inc.<\/b> Other, Consulting. <br><b>Lengo Therapeutics, Inc.; Link Immunotherapeutics; Medicxi, Mekanistic Therapeutics; Menarini Ricerche; Mersana; NANOBIOTIX; Nerviano Medical Sciences S.r.I. (NMS); Novo Nordisk Inc.<\/b> Other, Consulting. <br><b>Nurix Therapeutics; Ocellaris Pharma, Inc. & Eli Lilly; Partner Therapeutics; Pfizer Inc.; PIERRE FABRE; PYRAMID BIOSCIENCES; Qualigen Therapeutics; Roche,; RYVU THERAPEUTICS; Seattle Genetics<\/b> Other, Consulting. <br><b>Singzyme Pte Ltd; SK Life Science; SOTIO Biotechnology Co.; Senti Biosciences; Sun Pharma Advanced Research Company (SPARC); TheraTechnologies; Transcenta Therapeutics Inc.; Transgene<\/b> Other, Consulting. <br><b>Trillium Therapeutics Inc.; Venus Oncology; Verastem Oncology<\/b> Other, Consulting. <br><b>ADAGENE, Inc.; BIOINVENT; Boeringer Ingelheim International GmbH; Bright Peak Therapeutics; Cullinan Oncology; Elucida Oncology; EMD SERONO\/ MERCK KGaA; IMMUNOME; JAZZ; MIRATI; NBE THERAPEUTICS<\/b> Other, Advisory Board. <br><b>Nested Therapeutics, Inc.; Pheon Therapeutics; PYXIS Oncology; Roche; Spirea Limited Inc.; Vincerx; VRISE Therapeutics, Inc.; Zentalis Pharmaceuticals; ZielBio, Inc.<\/b> Other, Advisory Board. <br><b>NEXT Oncology San Antonio<\/b> Employment. <br><b>M. Barve, <\/b> <br><b>Mary Crowley Cancer Research<\/b> Employment. <br><b>A. Gabayan, <\/b> <br><b>Beverly Hills Cancer Center<\/b> Employment. <br><b>A. Vandross, <\/b> <br><b>Abbvie, Ascentage Pharma, Asana Bio(Kirilys), BioOneCure, Deciphera, Impact therapeutics, Nanjing Immunophage Biotech, Chugai Pharmaceutical Co, Gilead, Lyvgen Biopharma, Medikine, Mbrace Therapeutic<\/b> Other, PI on study. <br><b>Nitto therapeutics, NGMBio, OncoResponse, PMV Pharmaceuticals, Shuhai Yufan Biotechnologies, Immunomedics, siRNAomics, Tachyon Therapeutics, Teon Therapeutics, Kura, Exelixis, Xilio Development<\/b> Other, PI on study. <br><b>Vincerex, Tachyon Therapeutics, MBRACE therapeutics, bolt therapeutics, pliant therapeutics, vividion therapeutics.<\/b> Other, PI on study. <br><b>Pliant Pharmaceuticals<\/b> Other, Scientific Advisory Board. <br><b>Next Oncology Austin<\/b> Employment. <br><b>C. Cina, <\/b> <br><b>Nitto BioPharma, Inc.<\/b> Employment. <br><b>Y. Cohen-Arazi, <\/b> <br><b>Nitto BioPharma, Inc.<\/b> Employment. <br><b>Z. Albaugh, <\/b> <br><b>Theradex Oncology<\/b> Employment. <br><b>A. Huynh, <\/b> <br><b>Nitto BioPharma, Inc.<\/b> Employment. <br><b>J. Gullbo, <\/b> <br><b>Theradex Oncology<\/b> Employment. <br><b>S. Zabludoff, <\/b> <br><b>Nitto BioPharma, Inc.<\/b> Employment.","End":"4\/9\/2024 3:25:00 PM","HasWebcast":null,"Highlights":[],"Id":"11415","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT040","PresenterBiography":null,"PresenterDisplayName":"Annie Huynh, BS","PresenterKey":"16abf175-68b3-42d2-813b-453eceb26fc7","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT040. First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  2:30PM","SessionId":"665","SessionOnDemand":"False","SessionTitle":"Novel Agents and Emerging Therapeutic Strategies","ShowChatLink":"false","Start":"4\/9\/2024 3:15:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"5260f889-d365-46b5-b6b3-bd53bb087ca9","ControlNumber":"12161","DisclosureBlock":"","End":"4\/9\/2024 3:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11860","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"8","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  2:30PM","SessionId":"665","SessionOnDemand":"False","SessionTitle":"Novel Agents and Emerging Therapeutic Strategies","ShowChatLink":"false","Start":"4\/9\/2024 3:25:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"DNA damage response,PARP inhibitor,Phosphatidylinositol 3-kinase (PI3K) inhibitor,Tumor agnostic,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>T. Yap<\/b><sup>1<\/sup>, E. Dumbrava<sup>1<\/sup>, J. Rodon Ahnert<sup>1<\/sup>, A. Tsimberidou<sup>1<\/sup>, D. Hong<sup>1<\/sup>, S. Piha-Paul<sup>1<\/sup>, D. Karp<sup>1<\/sup>, S. Fu<sup>1<\/sup>, A. Naing<sup>1<\/sup>, P. Pohlmann<sup>1<\/sup>, J. Rhudy<sup>1<\/sup>, S. Berenji-Jalaei<sup>1<\/sup>, A. Cole<sup>1<\/sup>, C. Valladolid<sup>1<\/sup>, D. Dufner<sup>1<\/sup>, B. Bockorny<sup>2<\/sup>, A. Bullock<sup>2<\/sup>, D. Fein<sup>2<\/sup>, E. Buchbinder<sup>3<\/sup>, A. Choudhury<sup>3<\/sup>, C. Haddox<sup>3<\/sup>, E. Lee<sup>3<\/sup>, G. Wulf<sup>2<\/sup>, P. Ivy<sup>4<\/sup>, R. Said<sup>4<\/sup>, G. Shapiro<sup>3<\/sup>, F. Meric-Bernstam<sup>1<\/sup>; <br\/><sup>1<\/sup>UT MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Beth Israel Deaconess Medical Center, Boston, MA, <sup>3<\/sup>Dana Farber Cancer Institute, Boston, MA, <sup>4<\/sup>Cancer Therapy Evaluation Program (CTEP), National Institutes of Health – National Cancer Institute, Bethesda, MD","CSlideId":"","ControlKey":"c50eaafe-5472-433c-a91f-043b1f7ecc4a","ControlNumber":"10242","DisclosureBlock":"<b>&nbsp;T. Yap, <\/b> <br><b>University of Texas MD Anderson Cancer Center<\/b> Employment. <br><b>AbbVie, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Astex, AstraZeneca, Athena, Atrin, Avenzo, Avoro, Axiom, Baptist Health Systems, Bayer, Beigene, BioCity Pharma, Blueprint, Boxer<\/b> Other, Consultant. <br><b>Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Carrick Therapeutics, Circle Pharma, Clovis, Cybrexa, Daiichi Sankyo, Dark Blue Therapeutics, Diffusion, Duke Street Bio<\/b> Other, Consultant. <br><b>858 Therapeutics, EcoR1 Capital, Ellipses Pharma, EMD Serono, Entos, F-Star, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Ideaya Biosciences<\/b> Other, Consultant. <br><b>Idience, Ignyta, I-Mab, ImmuneSensor, Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI pharma, Mereo, Merck, Merit, Monte Rosa Therapeutics, Natera, Nested Therapeutics<\/b> Other, Consultant. <br><b>Nexys, Nimbus, Novocure, Odyssey, OHSU, OncoSec, Ono Pharma, Onxeo, PanAngium Therapeutics, Pegascy, PER, Pfizer, Piper-Sandler<\/b> Other, Consultant. <br><b>Pliant Therapeutics, Prolynx, Radiopharma Theranostics, Repare, resTORbio, Roche, Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2<\/b> Other, Consultant. <br><b>Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals, Tolremo, Tome, Thryv Therapeutics, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome, Voronoi Inc, Xinthera<\/b> Other, Consultant. <br><b>Zai Labs, ZielBio<\/b> Other, Consultant. <br><b>Acrivon, Artios, AstraZeneca, Bayer, Beigene, BioNTech, Blueprint, BMS, Boundless Bio, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono<\/b> Other, Grant\/Research Support. <br><b>Forbius, F-Star, GlaxoSmithKline, Genentech, Haihe, Ideaya ImmuneSensor, Insilico Medicine, Ionis, Ipsen, Jounce, Karyopharm, KSQ<\/b> Other, Grant\/Research Support. <br><b>Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tango<\/b> Other, Grant\/Research Support. <br><b>Tesaro, Vivace, Zenith<\/b> Other, Grant\/Research Support. <br><b>Seagen<\/b> Stock, Other, Stockholder.<br><b>E. Dumbrava, <\/b> None..<br><b>J. Rodon Ahnert, <\/b> None..<br><b>A. Tsimberidou, <\/b> None..<br><b>D. Hong, <\/b> None..<br><b>S. Piha-Paul, <\/b> None..<br><b>D. Karp, <\/b> None..<br><b>S. Fu, <\/b> None..<br><b>A. Naing, <\/b> None..<br><b>P. Pohlmann, <\/b> None..<br><b>J. Rhudy, <\/b> None..<br><b>S. Berenji-Jalaei, <\/b> None..<br><b>A. Cole, <\/b> None..<br><b>C. Valladolid, <\/b> None..<br><b>D. Dufner, <\/b> None.&nbsp;<br><b>B. Bockorny, <\/b> <br><b>Blueprint Medicines, Bioline Rx, Enlivex<\/b> Other, Advisory Board and Consultant. <br><b>Erytech Pharma<\/b> Travel. <br><b>Agenus Inc, NanoView Bioscience<\/b> Other, Research Funding.<br><b>A. Bullock, <\/b> None..<br><b>D. Fein, <\/b> None..<br><b>E. Buchbinder, <\/b> None..<br><b>A. Choudhury, <\/b> None..<br><b>C. Haddox, <\/b> None..<br><b>E. Lee, <\/b> None..<br><b>G. Wulf, <\/b> None..<br><b>P. Ivy, <\/b> None..<br><b>R. Said, <\/b> None..<br><b>G. Shapiro, <\/b> None..<br><b>F. Meric-Bernstam, <\/b> None.","End":"4\/9\/2024 3:40:00 PM","HasWebcast":null,"Highlights":[],"Id":"11417","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT042","PresenterBiography":null,"PresenterDisplayName":"Timothy Yap, MD;PhD","PresenterKey":"0715e96f-8ae5-4415-aeac-574b964cb9d9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT042. NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  2:30PM","SessionId":"665","SessionOnDemand":"False","SessionTitle":"Novel Agents and Emerging Therapeutic Strategies","ShowChatLink":"false","Start":"4\/9\/2024 3:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"10e796bd-fc88-4872-9c21-7ddeacc9d0e3","ControlNumber":"12162","DisclosureBlock":"","End":"4\/9\/2024 3:45:00 PM","HasWebcast":null,"Highlights":[],"Id":"11861","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"10","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  2:30PM","SessionId":"665","SessionOnDemand":"False","SessionTitle":"Novel Agents and Emerging Therapeutic Strategies","ShowChatLink":"false","Start":"4\/9\/2024 3:40:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT02-01 Phase 0 clinical trials,,"},{"Key":"Keywords","Value":"Glioblastoma,ATM inhibitor \/ ATM Kinase,Pharmacokinetics,Pharmacodynamics,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>N. Sanai<\/b><sup>1<\/sup>, S. Desai<sup>1<\/sup>, T. Margaryan<sup>1<\/sup>, J. Molloy<sup>1<\/sup>, C. LoCascio<sup>2<\/sup>, M. Elliott<sup>1<\/sup>, J. Harmon<sup>1<\/sup>, A. Hong<sup>1<\/sup>, E. Luna Melendez<sup>3<\/sup>, J. Wanebo<sup>1<\/sup>, K. Braun<sup>1<\/sup>, W. Kennedy<sup>1<\/sup>, M. Garcia<sup>1<\/sup>, W. Yoo<sup>1<\/sup>, A. Tovmasyan<sup>1<\/sup>, A.-C. Tien<sup>1<\/sup>, S. Mehta<sup>1<\/sup>; <br\/><sup>1<\/sup>Barrow Neurological Institute, Phoenix, AZ, <sup>2<\/sup>Dana-Farber Cancer Institute, Boston, MA, <sup>3<\/sup>RUSH Medical University, Chicago, IL","CSlideId":"","ControlKey":"44726c5a-b56c-484c-9e49-ac9a34c8a5c8","ControlNumber":"10797","DisclosureBlock":"&nbsp;<b>N. Sanai, <\/b> None..<br><b>S. Desai, <\/b> None..<br><b>T. Margaryan, <\/b> None..<br><b>J. Molloy, <\/b> None..<br><b>C. LoCascio, <\/b> None..<br><b>M. Elliott, <\/b> None..<br><b>J. Harmon, <\/b> None..<br><b>A. Hong, <\/b> None..<br><b>E. Luna Melendez, <\/b> None..<br><b>J. Wanebo, <\/b> None..<br><b>K. Braun, <\/b> None..<br><b>W. Kennedy, <\/b> None..<br><b>M. Garcia, <\/b> None..<br><b>W. Yoo, <\/b> None..<br><b>A. Tovmasyan, <\/b> None..<br><b>A. Tien, <\/b> None..<br><b>S. Mehta, <\/b> None.","End":"4\/9\/2024 3:55:00 PM","HasWebcast":null,"Highlights":[],"Id":"11795","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT044","PresenterBiography":null,"PresenterDisplayName":"Shwetal Mehta, PhD","PresenterKey":"e4afefc1-2766-4229-a8b5-e7255b83e32c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT044. A phase 0\/1b study of AZD1390 plus radiotherapy in newly-diagnosed, MGMT-unmethylated glioblastoma patients","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  2:30PM","SessionId":"665","SessionOnDemand":"False","SessionTitle":"Novel Agents and Emerging Therapeutic Strategies","ShowChatLink":"false","Start":"4\/9\/2024 3:45:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 0\/1b study of AZD1390 plus radiotherapy in newly-diagnosed, MGMT-unmethylated glioblastoma patients","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Glioblastoma,ATM,Radiation therapy,Safety,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. T. Yang<\/b><sup>1<\/sup>, P. Wen<sup>2<\/sup>, B. S. Imber<sup>1<\/sup>, J. Drappatz<sup>3<\/sup>, R. Jena<sup>4<\/sup>, D. Forst<sup>5<\/sup>, A. Zukas<sup>6<\/sup>, S. C. Short<sup>7<\/sup>, C. Fan<sup>8<\/sup>, W. Trigg<sup>9<\/sup>, A. Milner<sup>9<\/sup>, U. Polanska<sup>10<\/sup>, C. Glover<sup>9<\/sup>, C. Stavraka<sup>9<\/sup>, D. Dalal<sup>11<\/sup>, D. Karanovic<sup>8<\/sup>, A. J. Chalmers<sup>12<\/sup>; <br\/><sup>1<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY, <sup>2<\/sup>Center for Neuro-oncology, Dana-Farber Cancer Institute, Boston, MA, <sup>3<\/sup>University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>4<\/sup>University of Cambridge, Cambridge, United Kingdom, <sup>5<\/sup>Massachusetts General Hospital, Boston, MA, <sup>6<\/sup>Medical University of South Carolina, Charleston, SC, <sup>7<\/sup>Leeds Institute of Medical Research at St. James's, Leeds, United Kingdom, <sup>8<\/sup>AstraZeneca, Gaithersburg, MD, <sup>9<\/sup>AstraZeneca, Cambridge, United Kingdom, <sup>10<\/sup>AstraZeneca, Warsaw, Poland, <sup>11<\/sup>AstraZeneca, New York, NY, <sup>12<\/sup>School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom","CSlideId":"","ControlKey":"addab103-68bc-49d2-bf7d-8803bd3519e3","ControlNumber":"9883","DisclosureBlock":"<b>&nbsp;J. T. Yang, <\/b> <br><b>Galera Therapeutics<\/b> Independent Contractor. <br><b>Nanocan Therapeutics<\/b> Independent Contractor, Stock Option. <br><b>Kazia Therapeutics<\/b> Independent Contractor, Other, Research funding. <br><b>Plus Therapeutics<\/b> Independent Contractor, Research funding. <br><b>AstraZeneca<\/b> Independent Contractor, Other, Research funding. <br><b>Debiopharm<\/b> Other, Research funding. <br><b>Cantex Therapeutics<\/b> Research funding. <br><b>Biocept<\/b> Research funding. <br><b>P. Wen, <\/b> <br><b>Anheart;AstraZeneca;Black Diamond;Celularity;Chimerix;Day One Bio;Genenta;GlaxoSmithKline;Kintara;Merck;Mundipharma;Novartis;Novocure;Prelude Therapeutics;Sagimet;Sapience;Servier;Symbio;Tango;Telix;<\/b> Independent Contractor. <br><b>VBI Vaccines<\/b> Independent Contractor, Grant\/Contract. <br><b>AstraZeneca;Black Diamond;Bristol Myers Squibb;Chimerix;Eli Lilly;Erasca;Global Coalition For Adaptive Research;Kazia;MediciNova;Merck;Novartis;Quadriga;Servier<\/b> Grant\/Contract. <br><b>B. S. Imber, <\/b> <br><b>MSKCC<\/b> Employment. <br><b>AstraZeneca<\/b> Other, Research funding. <br><b>Kazia Therapeutics<\/b> Other, Research funding. <br><b>GT Medical Technologies<\/b> Other, Research funding, Advisory board. <br><b>Novartis<\/b> Other, Research funding. <br><b>Bayer<\/b> Other, Research funding. <br><b>Telix<\/b> Other, Advisory board. <br><b>J. Drappatz, <\/b> <br><b>Pfizer<\/b> Stock. <br><b>GlaxoSmithKline<\/b> Stock. <br><b>Gilead<\/b> Stock. <br><b>Novocure<\/b> Other, Research funding. <br><b>Servier<\/b> Other, Research funding. <br><b>Novartis<\/b> Other, Research funding. <br><b>Elsevier<\/b> Other Intellectual Property, Royalties. <br><b>Wolters Kluwer<\/b> Other Intellectual Property, Royalties.<br><b>R. Jena, <\/b> None.&nbsp;<br><b>D. Forst, <\/b> <br><b>Eli Lilly<\/b> Stock. <br><b>American Society of Clinical Oncology<\/b> Other, Receiving a Career Development Award.<br><b>A. Zukas, <\/b> None..<br><b>S. C. Short, <\/b> None.&nbsp;<br><b>C. Fan, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>W. Trigg, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>A. Milner, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>U. Polanska, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>C. Glover, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>C. Stavraka, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>D. Dalal, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>D. Karanovic, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>A. J. Chalmers, <\/b> <br><b>AstraZeneca<\/b> Other, Research funding and honoraria.","End":"4\/9\/2024 4:05:00 PM","HasWebcast":null,"Highlights":[],"Id":"11418","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT043","PresenterBiography":null,"PresenterDisplayName":"Jordan Best","PresenterKey":"09caff0e-0e82-4e63-92a0-4dbc38fa90bc","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT043. Safety and preliminary efficacy of AZD1390 + radiation therapy (RT) for glioblastoma (GBM)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  2:30PM","SessionId":"665","SessionOnDemand":"False","SessionTitle":"Novel Agents and Emerging Therapeutic Strategies","ShowChatLink":"false","Start":"4\/9\/2024 3:55:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Safety and preliminary efficacy of AZD1390 + radiation therapy (RT) for glioblastoma (GBM)","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"a48762e1-2eea-4489-8e2e-9c209059e08d","ControlNumber":"12164","DisclosureBlock":"","End":"4\/9\/2024 4:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"11863","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"13","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  2:30PM","SessionId":"665","SessionOnDemand":"False","SessionTitle":"Novel Agents and Emerging Therapeutic Strategies","ShowChatLink":"false","Start":"4\/9\/2024 4:05:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"ddb9dbed-709d-495a-b305-988b24352a28","ControlNumber":"12163","DisclosureBlock":"","End":"4\/9\/2024 4:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"11862","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"14","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  2:30PM","SessionId":"665","SessionOnDemand":"False","SessionTitle":"Novel Agents and Emerging Therapeutic Strategies","ShowChatLink":"false","Start":"4\/9\/2024 4:15:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""}]